Devolver Digital Reports Strong FY 2025 Growth with Historic Steam Milestone

Revenue tops $100M, EBITDA beats consensus, and a historic Steam Top 10 hat-trick for Devolver Digital. A cleaner story with costs down and cash up.

Hide Me

Written By

Joshua
Reading time
» 5 minute read 🤓
Share this

Unlock exclusive content ✨

Just enter your email address below to get access to subscriber only content.
Join 126 others ⬇️
Written By
Joshua
READING TIME
» 5 minute read 🤓

Un-hide left column

Devolver Digital FY 2025 Trading Update: Revenue Tops US$100m and Profitability Improves

Devolver Digital has delivered another step forward in FY 2025. Management says full-year revenue exceeded US$100 million, right in line with prior guidance, with strength weighted to the second half thanks to platform deals and September’s Steam Publisher Sale. Adjusted EBITDA (a proxy for operating profit before interest, tax, depreciation and amortisation) improved year-on-year, with the company flagging an “underlying” pre-impairments figure in USD double-digit millions that was marginally above consensus.

There’s also a notable balance sheet anchor: c.US$36.4 million net cash at 31 December 2025. All told, this is a cleaner, more disciplined Devolver than the one investors wrestled with in 2023 – and that matters.

Key numbers from the trading update

Metric FY 2025 / Status Notes
Revenue More than US$100 million Met guidance, driven by strong H2 including platform deals and the September Steam Publisher Sale
Adjusted EBITDA (pre-impairments) USD double-digit millions Marginally above consensus; “underlying” figure before title performance impairments
Title performance impairments c.US$3.5 million For released title underperformance; these are included in Adjusted EBITDA per company definition
Net cash c.US$36.4 million As at 31 December 2025
Average Metacritic score 78 Across 2025 releases
Operating expenses Down slightly year-on-year Ongoing cost discipline into 2026
January 2026 milestone 3 titles in Steam Global Best Sellers Top 10 Woolhaven, Cult of the Lamb and Quarantine Zone: The Last Check
Results date April 2026 Full audited FY 2025 numbers due

Second-Half Strength: Platform Deals and a Well-Timed Steam Sale

The H2 weighting matters. Management highlights the timing of platform deals and the September Steam Publisher Sale as key contributors to the strong finish. Steam is the dominant global PC storefront, so featuring in its promotional beats can materially lift sell-through and catalogue monetisation.

My read: momentum was built, not borrowed. While deal timing helps, Devolver’s portfolio seems to be doing more of the heavy lifting than in 2023, which boosts confidence in repeatability.

High-Quality Releases: Metacritic 78 and Several Breakouts

Quality is holding up. New 2025 releases averaged a 78 on Metacritic, which is a solid badge of critical reception. Specific standouts included Monster Train 2 (via Devolver’s Big Fan label), Stronghold: Crusader (from its Firefly studio), and viral hit Ball x Pit. Lower-cost titles Mycopunk and Look Outside also exceeded expectations with strong user feedback.

System Era continued to contribute through Astroneer’s second paid DLC (PDLC) “Megatech” in November. PDLC – paid downloadable content – extends the revenue tail of existing titles with new content drops, a sensible lever in a hit-driven market.

Adjusted EBITDA and Impairments: What’s Under the Bonnet

Adjusted EBITDA is flagged “pre-impairments” at USD double-digit millions, marginally above consensus. Separately, Devolver estimates c.US$3.5 million of impairments tied to underperforming released titles. Per the company’s definition, title performance impairments are included in Adjusted EBITDA, while goodwill and acquired IP impairments are excluded.

Translation: management is showing an “underlying” profitability figure before those title-specific write-downs, and also being transparent about the hit. The impairments number is not huge in group context and suggests portfolio underperformance is being contained rather than systemic.

Costs Are Tighter, and the Cash Buffer is Solid

Operating expenses fell slightly year-on-year, confirming the ongoing cost-discipline narrative. There’s also c.US$36.4 million net cash on the balance sheet at year-end. That gives Devolver optionality – to market titles properly, partner selectively, and invest where the greenlight process (the internal gating for new game investments) says risk-reward is attractive.

It won’t eliminate volatility – games are hits-driven – but a clean balance sheet lowers execution risk and reduces dependency on external capital.

2026 Starts Hot: Steam Top 10 Hat-Trick and Cult of the Lamb’s Woolhaven

Early 2026 trading looks lively. Quarantine Zone: The Last Check is exceeding expectations in its first weeks. Cult of the Lamb’s Woolhaven PDLC is getting rave reviews. Notably, January saw three Devolver titles – Woolhaven, Cult of the Lamb and Quarantine Zone: The Last Check – in Steam’s Global Best Sellers Top 10 simultaneously, a first in the company’s history. That is powerful evidence of reach and relevance on the world’s biggest PC storefront.

Why this matters: a hot January should provide a strong Q1 base, lifts catalogue visibility, and can improve conversion on future promotions.

Strategy Update: From the 2023 Trough to Sustainable Profitability

Management highlights a suite of changes begun three years ago – a tighter greenlight process, in-house tech, cost cutting, and improved store management – as catalysts for the turnaround from 2023’s trough. The message is consistent: these changes are maturing, and as older projects cycle out, the quality and profitability of the slate should rise.

The pipeline remains healthy too: more than 30 titles slated for the next three years, balanced across third-party and own-IP, plus in-house studios and a complementary publishing brand.

Why It Matters for Investors: My Take

  • Positives: Revenue above US$100 million, underlying EBITDA ahead of expectations, cost base trending down, and a meaningful net cash position. The Steam Top 10 milestone in January is a tangible proof point.
  • Watch-outs: c.US$3.5 million of title impairments shows some variability within the slate. H2 weighting was helped by deal and sale timing, which may not repeat on the same cadence.
  • What could move the needle next: detailed FY 2025 results in April (including reported Adjusted EBITDA post-impairments), performance longevity for Quarantine Zone and Woolhaven, and confirmation that 2026 slate quality holds near that 78 Metacritic bar.

Bottom Line: A Cleaner Story with Building Momentum

This update reads positively. Devolver met revenue guidance, nudged profitability above expectations on an underlying basis, kept costs in check, and heads into 2026 with genuine momentum on Steam. It is not risk-free – the games business never is – but the operational discipline and cash cushion make the trajectory look sturdier than a year ago.

Full audited numbers land in April 2026. If current trading holds, Devolver looks set for further profit improvement this year.

Disclaimer: This Blog is provided for general information about investments. It does not constitute investment advice. Information is taken from publicly available sources and any comment is that of the author who does not take any third party comment in the publication.
Last Updated

February 9, 2026

Category
Views
14
Likes
0

You might also enjoy 🔍

Minimalist digital graphic with a yellow-orange background, featuring 'Investing' in bold white letters at the centre and the 'Joshua Thompson' logo below.
Author picture
Aberdeen UK Smaller Cos NAV fell 3.5% amid style headwinds, but hiked its interim dividend 21.6% to 4.50p per share.
This article covers information on Aberdeen UK Smaller Cos. Grwth Trst.
Minimalist digital graphic with a yellow-orange background, featuring 'Investing' in bold white letters at the centre and the 'Joshua Thompson' logo below.
Author picture
HUTCHMED’s 2025 profits hit $457M from a major divestment, while China sales rebound and its novel ATTC cancer platform enters clinical trials.
This article covers information on Hutchmed (China) Limited.

Comments 💭

Leave a Comment 💬

No links or spam, all comments are checked.

First Name *
Surname
Comment *
No links or spam - will be automatically not approved.

Got an article to share?